Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol

Blood Pressure Clinical Trial

Official title:

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02871362
• Other study ID #: INQ/030915
• Status: Completed
• Phase: N/A
• Start date: March 17, 2017
• Est. completion date: January 30, 2018

Study information

• Verified date: February 2019
• Source: InQpharm Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-118 on the systolic and diastolic blood pressure (BP) and to explore the effects on parameters of lipid metabolism in subjects with elevated BP and low density lipoprotein cholesterol (LDL-C) levels in a pilot study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: January 30, 2018
• Est. primary completion date: January 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Caucasian males and females, 18-65 years of age

2. Body mass index (BMI) 18.5-29.9 kg/m2

3. Generally in good health, in particular an electrocardiogram (ECG) without pathological findings at screening

4. High normal BP levels (130-139 / 85-89) for 20% of randomized subjects and hypertension grade 1 (140-159 / 90-99) BP levels for 80% of randomized subjects at screening (mean of the 2nd and 3rd measurement during the assessment in triplicate at screening) and at baseline (mean of the 2nd and 3rd measurement during the assessment in triplicate at week 0)

5. LDL-C 100-159 mg/dL

6. Readiness to comply with study procedures, in particular:

• Consumption of the IP during the entire study

• Maintaining the habitual diet, with the exception of consumption of maximal 2 garlic cloves per week

• Accepting blood draws

• Complying with requirements for BP measurements (such as avoiding any strenuous exercise and stimulants (alcohol, caffeine) for at least 24 h before the measurement; refraining from extreme cold and heat exposure and food and fluid intake for at least 1 h before the measurement)

• Filling in health questionnaires

7. Non-smoker / smoking cessation of last =12 months prior to screening

8. Stable body weight in the last 3 months prior to screening (<3 kg self-reported change)

9. If allowed concomitant medications are taken this must have been stable at least during the last month prior to screening

10. Women of child-bearing potential only:

1. negative pregnancy testing (ß-HCG in urine at screening)

2. commitment to use reliable contraception methods during the entire study Participation is based upon written informed consent form (ICF) by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

Exclusion Criteria:

1. Known sensitivity to any components of the IP

2. Clinically significant disturbances in lipid metabolism

3. Known genetic hyperlipidemia

4. Known secondary hypertension

5. Known white-coat hypertension

6. Known type-1-diabetes

7. Uncontrolled or within the last 6 months prior to screening diagnosed type-2-diabetes

8. Untreated or non-stabilized thyroid disorder

9. History and/or presence of clinically significant cardiovascular disease as per investigator's judgement:

1. Known congenital heart defects

2. Myocardial infarction, heart failure, angina pectoris, life-threatening arrhythmia or stroke within the last 6 months prior to screening

3. Existing thrombosis or disposition to thrombosis

10. Any other known significant or serious condition / disease that renders subjects ineligible, e.g.:

1. History of malignancy within the past 5 years prior to screening

2. Bleeding disorder and/or need for anticoagulants (anti-platelet agents are allowed)

3. Current psychiatric care and/or use of neuroleptics

4. Bariatric surgery in the last 12 months prior to screening

11. Any known metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subject

12. Known arm lymphedema (e.g. due to mastectomy)

13. Other clinically relevant excursions of safety parameters and/or deviations > 2 x ULN (upper limit of normal)

14. Dietary habits that may interfere with the study objectives:

1. Eating disorder

2. Subjects with dietary restriction that may affect the study outcome

3. Participation in a weight loss program

15. Use of drugs or supplements that can influence SBP or DBP (e.g. ACE inhibitors, diuretics, calcium channel or ß-blockers, grape seed extract, coenzyme Q10 etc.) within the last 4 weeks prior to screening and during the study

16. Use of lipid lowering drugs (affecting lipid metabolism, platelet function or antioxidant status, etc.) OR dietary or health supplements (e.g. omega-3 fatty acids, green tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as e.g. Becel), oat fiber, niacin, soy protein, psyllium seed husk, glucomannan, chitosan or probiotics/prebiotics) within the last 4 weeks prior to screening and during the study

17. Use of drugs that can influence cholesterol levels (e.g. corticosteroids, amiodarone, estrogen, anabolic ster-oids)

18. Use of weight loss treatment

19. Use of any recreational drugs

20. Alcohol abuse (men: =21 units/week, women: =14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

21. Women of child-bearing potential: pregnant or breast-feeding

22. Participation in another study or blood donation during the last 30 days prior to screening

23. Any other reason deemed suitable for exclusion as per investigator's judgment, e.g.:

1. Insufficient compliance with study procedures

2. Inability to communicate with the site study staff

Related Conditions & MeSH terms

• Blood Pressure
• Low Density Lipoprotein Cholesterol Level

Intervention

Dietary Supplement:
• IQP-AS-118
Take one a day
• Placebo
Take one a day

Locations

Country	Name	City	State
Germany	analyze & realize GmbH	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
InQpharm Group

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Pressure (Systolic & Diastolic)	Week 12 vs. week 0	12 weeks
Secondary	Systolic blood pressure	Week 4 and week 8 vs. week 0, respectively	12 weeks
Secondary	Diastolic blood pressure	Week 4 and week 8 vs. week 0, respectively	12 weeks
Secondary	Fasting LDL-C concentration and non-HDL-C	Week 12 vs. week 0	12 weeks
Secondary	Fasting TC Concentration	Week 12 vs. week 0	12 weeks
Secondary	Fasting HDL-C Concentration	Week 12 vs. week 0	12 weeks
Secondary	Fasting TG Concentration	Week 12 vs. week 0	12 weeks
Secondary	Fasting LDL-C/HDL-C and TC/HDL-C ratio	Week 12 vs. week 0	12 weeks
Secondary	Fasting Lp (a) concentrations	Week 12 vs. week 0	12 weeks
Secondary	hs-CRP	Week 12 vs. Screening	12 weeks
Secondary	Homocysteine	Week 12 vs. Screening	12 weeks
Secondary	Pulse wave assessment	Week 12 vs. week 0	12 weeks
Secondary	Metabolome analysis	Week 12 vs. week 0	12 weeks
Secondary	SF-12	Week 4, week 9 and week 12 vs. week 0, respectively	12 weeks
Secondary	Global evaluation of benefit by the subjects/ investigator	Week 12 only	12 weeks